Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第3页

Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-03-28 DOI: 10.1080/14737167.2025.2483423

Shan Zhao, Shuo Kang

{"title":"Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China.","authors":"Shan Zhao, Shuo Kang","doi":"10.1080/14737167.2025.2483423","DOIUrl":"10.1080/14737167.2025.2483423","url":null,"abstract":"Background: The cost-effectiveness of tislelizumab plus chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC) was uncleared yet. The current analysis aimed to evaluate the cost-effective of adding tislelizumab to the first-line chemotherapy for patients with untreated ES-SCLC from the Chinese health-care system perspective.Research design and methods: A partitioned survival model that simulated 3-week patients transition in 10-year time horizon was established to evaluate the economic value. The clinical benefit and safety data were gathered from the RATIONALE-312 trial, model parameters were gathered from the local charges and previously published studies. Sensitivity analyses and subgroup analyses were conducted to examine the robustness of the model outcomes.Results: Tislelizumab plus chemotherapy could bring additional 0.61 LYs and 0.30 QALYs with the marginal cost of $5,849.40, resulting in the incremental cost-effectiveness ratio (ICER) of $19,592.08 per additional quality-adjusted life-years (QALYs) gained. Sensitivity analyses and subgroup analyses confirmed the robustness of the model results for both intention-to-treat patients and all subgroup patients.Conclusions: Tislelizumab plus chemotherapy could be considered cost-effective first-line therapy for patients with untreated ES-SCLC patients compared with chemotherapy alone from the perspective of Chinese health-care system.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-7"},"PeriodicalIF":1.8,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-03-26 DOI: 10.1080/14737167.2025.2482661

Carlo Lazzaro, Giovanni Fattore, Angelo Guido Corsico

{"title":"COVID-19-related hospitalizations in Italy: an application of the synthetic control method to investigate the trajectory of diagnosis-related group 79 and its counterfactual during 2010-2021.","authors":"Carlo Lazzaro, Giovanni Fattore, Angelo Guido Corsico","doi":"10.1080/14737167.2025.2482661","DOIUrl":"10.1080/14737167.2025.2482661","url":null,"abstract":"Background: With 10.95 million cases (11 March 2020-9 February 2022), Italy was massively hit by the coronavirus disease 2019 (COVID-19) pandemic. Most of the COVID-19-related inpatient discharges were codified under the Diagnosis-Related Group (DRG) 79. During 2019-2021, DRG 79 inpatient discharges increased from 20,377 to 130,580 (+540.82%).Research design and methods: To investigate the causal relationship between DRG 79 inpatient discharges and COVID-19, the synthetic control method (SCM) compared the real with the counterfactual DRG 79. The latter was a weighted combination of control units (22 DRGs unrelated to COVID-19). The SCM mimicked the trajectory of DRG 79 in the absence of COVID-19.Placebo studies and robustness test investigated the reliability of the baseline findings.Results: Six out of the 22 control units contribute to the counterfactual DRG 79. The real and the counterfactual DRG 79 cease to overlap from 2019 onward. Placebo studies and robustness test confirm the causal relationship of COVID-19 with the increased number of inpatient discharges coded under DRG 79 during 2019-2021.Conclusion: The SCM identifies a causal link between COVID-19 and DRG 79 in Italy. Hopefully, future contributions will utilize SCM (and causal inference in general) in health care decision-making within the Italian National Health Service.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-13"},"PeriodicalIF":1.8,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-03-25 DOI: 10.1080/14737167.2025.2482667

Ying Liu, Xiaoning He

{"title":"Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China.","authors":"Ying Liu, Xiaoning He","doi":"10.1080/14737167.2025.2482667","DOIUrl":"10.1080/14737167.2025.2482667","url":null,"abstract":"Background: Mitoxantrone hydrochloride liposome (PLM60) is a novel liposome formulation, approved in China for the treatment of patients diagnosed with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This study aimed to assess the cost-effectiveness of PLM60 versus chidamide (CS055) in R/R PTCL from the Chinese healthcare perspective.Research design and methods: We conducted a cost-utility analysis using a partitioned survival model with a 5-year horizon, applying a 5% discount rate to both costs and health outcomes. Owing to the lack of head-to-head comparison between the two drugs, we employed an unanchored matching-adjusted indirect comparison (MAIC) to estimate relative efficacy and safety outcomes. Utility values and costs were obtained from published literature and clinical expert consultations. Sensitivity analyses were performed to evaluate the robustness of results.Results: In the base case analysis, PLM60 saved Chinese Yuan 77,397 (226,075 vs. 303,472) and gained an additional 0.10 (1.30 vs. 1.20) quality-adjusted life years compared to CS055, making it the strongly dominant treatment option. Comprehensive sensitivity analyses confirmed the robustness of the results.Conclusion: PLM60 was estimated to be a cost-effective treatment for R/R PTCL compared with CS055 from a Chinese healthcare perspective, which provided patients with an effective and cost-saving treatment option.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of nintedanib versus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-03-24 DOI: 10.1080/14737167.2025.2480718

Aziz Rezapour, Mohammad Veysi-Sheikhrobat, Aghdas Souresrafil, Sajad Moeini, Tayebe Roghani, Abdollah Sayyad, Ahmad Tahmasebi-Ghorrabi

{"title":"Cost-effectiveness of nintedanib versus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review.","authors":"Aziz Rezapour, Mohammad Veysi-Sheikhrobat, Aghdas Souresrafil, Sajad Moeini, Tayebe Roghani, Abdollah Sayyad, Ahmad Tahmasebi-Ghorrabi","doi":"10.1080/14737167.2025.2480718","DOIUrl":"10.1080/14737167.2025.2480718","url":null,"abstract":"Introduction: Objective: To systematically review studies on the cost-effectiveness of pirfenidone compared to nintedanib in patients with idiopathic pulmonary fibrosis (IPF).Methods: Data sources: PubMed, EMBASE, Scopus, and Web of Science. Inclusion criteria: Full economic evaluations comparing pirfenidone versus nintedanib inIPF patients. Assessment: Quality of Health Economic Studies (QHES) tool forstudy quality.Results: Nine studies met the inclusion criteria with QHES scores of 0.91 or higher. The incremental cost-effectiveness ratios (ICERs) ranged from $66,434 to $1,668,321 per quality-adjusted life year (QALY) in the United States. Nintedanib was found to be cost-effective in five studies.Conclusions: Nintedanib appears to be a more cost-effective treatment for IPF compared to pirfenidone. Further research is needed, particularly in low- and middle-income countries, considering healthcare system perspectives and varied willingness-to-pay thresholds.Registration: PROSPERO (CRD42024543954).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of long-term overall survival with extrapolated overall survival for pembrolizumab assessed by Australian reimbursement authorities.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-03-20 DOI: 10.1080/14737167.2025.2478234

Francis C Dehle, Kevin Phan, Jerome Higgins, Kate Applegarth, Manoj Gambhir, Colman B Taylor

{"title":"Comparison of long-term overall survival with extrapolated overall survival for pembrolizumab assessed by Australian reimbursement authorities.","authors":"Francis C Dehle, Kevin Phan, Jerome Higgins, Kate Applegarth, Manoj Gambhir, Colman B Taylor","doi":"10.1080/14737167.2025.2478234","DOIUrl":"https://doi.org/10.1080/14737167.2025.2478234","url":null,"abstract":"Background: Decisions about government funding for new medicines often rely on statistical models to predict how long patients will live (overall survival, OS) based on early trial data. This study compared the accuracy of these predictions for the cancer drug pembrolizumab, using models preferred by pharmaceutical companies (Sponsors) and the Pharmaceutical Benefits Advisory Committee (PBAC), compared to real-world long-term follow-up (LTFU) data.Research design and methods: We reviewed publicly available PBAC summary documents (PSDs) for all funding decisions on pembrolizumab up to November 2022. We included cases with at least three years of follow-up data and where at least 350 patients per year would be treated. We then compared survival predictions from PBAC and Sponsor models to actual survival data at two time points.Results: A total over 38 PSDs covering 15 indications, five met our criteria. Sponsor-preferred models underestimated real survival by 0.54% to 16.45%, while PBAC-preferred models underestimated survival by 1.20% to 24.21%.Conclusion: Results demonstrate that OS extrapolation methods used by both the Sponsor and PBAC tend to underestimate long-term survival outcomes for pembrolizumab indications, with PBAC-preferred methods being more conservative.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-03-19 DOI: 10.1080/14737167.2025.2479131

Giovanni Tafuri, Andrea Bracco, Jens Grueger

{"title":"Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update.","authors":"Giovanni Tafuri, Andrea Bracco, Jens Grueger","doi":"10.1080/14737167.2025.2479131","DOIUrl":"10.1080/14737167.2025.2479131","url":null,"abstract":"Introduction: In a previous publication, we provided an overview of the current situation of patient access to orphan drugs in the European Union (EU), of the evolving rare disease policy landscape and recommendations for areas of improvement throughout the lifecycle of orphan drugs. This article aims to provide an update on evolving new policies impacting access to orphan drugs in the European Union from a health technology developer perspective.Areas covered: We provide an update on the emerging competitiveness gap in the pharmaceutical sector between the EU and the United States. We discuss the latest developments of the European Commission's revision proposal of the EU's pharmaceutical legislation and the threats and opportunities of the new HTA Regulation with a focus on orphan drugs. Additionally, we present the latest policy updates from Germany and the United Kingdom impacting orphan drug developers.Expert opinion: While our initial set of recommendations remains unchanged, the policy landscape for orphan drugs seems to be deteriorating both at the EU and at the Member State level.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-7"},"PeriodicalIF":1.8,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-03-15 DOI: 10.1080/14737167.2025.2480123

Yanghaotian Wu, Jingfu Qiu

{"title":"The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China.","authors":"Yanghaotian Wu, Jingfu Qiu","doi":"10.1080/14737167.2025.2480123","DOIUrl":"https://doi.org/10.1080/14737167.2025.2480123","url":null,"abstract":"Background: The Chinese government launched a comprehensive reform of public hospitals, including a zero-markup drug policy (ZMDP) and adjustments to the price compensation mechanism for medical services. We aimed to assess the impact of the reform on economic burden for chronic obstructive pulmonary disease (COPD) inpatients.Research design and methods: Health care institutions were selected using judgmental sampling. Structural variation analysis was conducted to assess changes in the cost structure. An interrupted time series analysis was used to evaluate level and trend changes in medical costs.Results: After the reform, the total cost, western medicine cost, and traditional Chinese medicine cost per visit decreased significantly, with monthly downward trends (p < 0.05). The proportion of western medicine cost decreased by 5.59%, but remained the main composition (31.78%). The health insurance payments, out-of-pocket (OOP) cost per visit, and OOP cost proportion decreased significantly (p < 0.05). The health insurance payments per visit showed a monthly downward trend (p < 0.001), and the decline in OOP cost per visit extended (p = 0.003).Conclusions: The reform reduced the economic burden of COPD inpatients, optimized the cost structure and improved the efficiency of health insurance utilization. However, the short-term substitution effect of medical services on medicines weakened the cost-reduction effect.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indication-based pricing of the pharmaceuticals in Croatia: case-study.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-03-14 DOI: 10.1080/14737167.2025.2478232

Ana Bobinac, Luka Vončina, Ismar Velić, Elizabeta Ribarić, Vanesa Benković

{"title":"Indication-based pricing of the pharmaceuticals in Croatia: case-study.","authors":"Ana Bobinac, Luka Vončina, Ismar Velić, Elizabeta Ribarić, Vanesa Benković","doi":"10.1080/14737167.2025.2478232","DOIUrl":"10.1080/14737167.2025.2478232","url":null,"abstract":"Background: Rising pharmaceutical expenditure worldwide, including in Croatia, is putting considerable pressure on healthcare budgets. Oncology drugs, often used in several indications with varying efficacy, contribute to this challenge, and a single price is paid regardless of the indication. This study investigates whether indication-based pricing (IBP), a method of pricing the same drug for different indications based on its relative value in different treatment applications, could be a potential solution to contain drug expenditure.Research design and methods: We operationalized IBP in two ways: by anchoring all drug prices according to the indication that provides the most or least benefit, and second, by anchoring drug prices to a cost-effectiveness threshold estimated for Croatia. We also interviewed policymakers in Croatia to determine whether they are familiar with the problem of differential effectiveness of medicines with multiple indications.Results: Applying IBP to the oncology drug abiraterone in three indications, as measured by life-years gained (LYGs) and quality-adjusted life-years (QALYs), shows the effectiveness of abiraterone varies considerably by indication. Depending on the IBP approach chosen, drug prices can be reduced by 74% or increased by up to 280%.Conclusions: Drug prices can vary dramatically depending on the IBP approach chosen.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychometric properties of outcome measures for freezing of gait in Parkinson's disease: a systematic review and meta-analysis.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-03-13 DOI: 10.1080/14737167.2025.2477473

Prisca Proietti, Ilaria Ruotolo, Alessandra Carlizza, Alessandro Ugolini, Giovanni Galeoto, Giovanni Fabbrini, Giovanni Sellitto

{"title":"Psychometric properties of outcome measures for freezing of gait in Parkinson's disease: a systematic review and meta-analysis.","authors":"Prisca Proietti, Ilaria Ruotolo, Alessandra Carlizza, Alessandro Ugolini, Giovanni Galeoto, Giovanni Fabbrini, Giovanni Sellitto","doi":"10.1080/14737167.2025.2477473","DOIUrl":"10.1080/14737167.2025.2477473","url":null,"abstract":"Introduction: This systematic review and meta-analysis evaluated validated tools for assessing FOG in PD, focusing on their psychometric properties, linguistic adaptations, and methodological quality.Methods: A systematic search was conducted in MEDLINE, CINAHL, SCOPUS, and Web of Science, following PRISMA-COSMIN guidelines. Studies assessing validity, reliability, and cross-cultural adaptation of FOG-specific tools were included. Key psychometric properties, such as internal consistency (Cronbach's alpha) and test-retest reliability (Intraclass Correlation Coefficient, ICC), were extracted. The COSMIN Risk of Bias checklist was used to assess methodological quality, and meta-analyses were performed for comparable studies.Results: Six validated tools were identified, with FOG-Q and NFOG-Q emerging as the most robust. Meta-analysis showed high internal consistency (FOG-Q: α = 0.90; NFOG-Q: α = 0.87-0.89) and test-retest reliability (FOG-Q ICC = 0.87), though substantial heterogeneity was noted (I² = 71.1-86.4%). Emerging tools, including CFOG-Q, Ziegler test, and DYPAGS, addressed cognitive and dual-tasking aspects but lacked linguistic validation.Conclusion: FOG-Q and NFOG-Q remain widely used, yet NFOG-Q may have limitations in detecting small clinical changes. Broader linguistic adaptations are needed, and emerging tools hold promise for multidimensional assessment. Future research should integrate subjective and objective measures for comprehensive evaluations.Registration: PROSPERO (CRD42020173873).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-13"},"PeriodicalIF":1.8,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-03-12 DOI: 10.1080/14737167.2025.2478241

Nan Fang, Xuan Xia, Xiaoning He

{"title":"Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China.","authors":"Nan Fang, Xuan Xia, Xiaoning He","doi":"10.1080/14737167.2025.2478241","DOIUrl":"10.1080/14737167.2025.2478241","url":null,"abstract":"Background: Chemotherapy-induced myelosuppression (CIM) is the most common adverse event associated with chemotherapy. The recently approved novel pharmacotherapy trilaciclib demonstrates potential to provide multilineage protection against CIM. This study aimed to evaluate the cost-effectiveness of trilaciclib among patients with extensive-stage small cell lung cancer (ES-SCLC) in China.Research design and methods: A short-term Markov model and long-term partitioned survival model were developed to simulate disease progression during and after chemotherapy over a lifetime horizon. Clinical, cost, and utility parameters were obtained from three pivotal clinical trials of trilaciclib, published literature, and expert opinion. Total cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated. Scenario analyses and sensitivity analyses assessed model robustness.Results: The lifetime incremental cost per patient for trilaciclib was CN¥22,828 (US$3,210), with an incremental QALY of 0.093, yielding an ICER of CN¥245,841 (US$34,565) per QALY gained. This ICER falls below China's willingness-to-pay threshold of three times per-capita GDP (CN¥268,074, US$37,691). Extensive sensitivity analyses confirmed the robustness of the base-case findings.Conclusions: Trilaciclib represents a cost-effective option for reducing the incidence of CIM in ES-SCLC patients. These results support reimbursement decisions and pricing strategies for trilaciclib in China.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0